Amador Flores

Dr. Amador Flores


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2023 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
AFAmador Flores
Amador Flores
JZJosé Luis Zacarías-Hernández
José Luis Zacarías-Hernández
CVCecilia Gabriela Vázquez-Cortés
Cecilia Gabriela Vázquez-Cortés
RTReyes S Tamez-Guerra
Reyes S Tamez-Guerra
MOManuel De la O-Cavazos
Manuel De la O-Cavazos
CRCristina Rodríguez-Padilla
Cristina Rodríguez-Padilla
Introduction: Tuberculosis (TB) is a re-emerging disease considered a public health concern. In the present study, we analyzed the epidemiology and drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary TB. Methodology: Mycobacterium tuberculosis isolates (n = 190) were obtained from patients with pulmonary TB admitted to Dr. José Eleuterio González University Hospital (UH). Each M. tuberculosis isolate was analyzed by spoligotyping (spacer oligonucleotide typing) and MIRU-VNTR (Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeat). Drug resistance was evaluated using the Anyplex™ II MTB/MDR/XDR assay. Results: The predominant spoligotypes observed were X1 (SIT 119, n = 46), T1 (SIT 53, n = 40), H3 (SIT 50, n = 13), Beijing (SIT 1, n = 11), and EAI2-Manila (SIT 19, n = 8). MIRU-VNTR analysis showed that the locus QUB-26 had the highest allelic variability. The observed drug resistance included monoresistance to rifampicin (2.6%; n = 5), isoniazid (3.2%; n = 6), and fluoroquinolones (1.6%; n = 3) as well as multidrug resistance (5.3%; n = 10). All of the Beijing strains were susceptible. Regarding comorbidities, 13.7% (26/190) of the patients were co-infected with TB and HIV (TB+HIV+), and 31.6% (55/190) had TB along with diabetes (TB + diabetes). Conclusions: The most prevalent lineages were X1 (SIT 119; 24.3%) and T1 (SIT 53; 21%). An alarming proportion (12.6%) of M. tuberculosis isolates presented drug resistance. To effectively manage TB, continuous surveillance of regional strain dissemination, drug resistance profiles, and TB-associated comorbidities is crucial.

24 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NMNatalia Martinez-Acuña
Natalia Martinez-Acuña
Diana Nolazco-AvalosDiana Nolazco-Avalos
Diana Nolazco-Avalos
DRDiana Raquel Rodríguez-Rodríguez
Diana Raquel Rodríguez-Rodríguez
CMCynthia Gabriela Martinez-Liu
Cynthia Gabriela Martinez-Liu
KGKame Galan-Huerta
Kame Galan-Huerta
ARAna M. Rivas-Estilla
Ana M. Rivas-Estilla
The progression and distribution of the SARS-CoV-2 pandemic are continuously changing over time and can be traced by blood donors’ serological survey. Here, we investigated the seroprevalence of anti-SARS-CoV-2 antibodies in blood donors in Nuevo Leon, Mexico during 2020 as a strategy for the rapid evaluation of the spread of SARS-CoV-2 and asymptomatic case detection. We collected residual plasma samples from blood donors who attended two regional donation centers from January to December of 2020 to identify changes in anti-SARS-CoV-2 IgG prevalence. Plasma samples were analyzed on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG chemiluminescent assay. We found a total of 99 reactive samples from 2068 analyzed plasma samples, resulting in a raw prevalence of 4.87%. Donors aged 18–49 years were more likely to be seropositive compared to those aged >50 years (p < 0.001). Weekly seroprevalence increased from 1.8% during the early pandemic stage to 27.59% by the end of the year. Prevalence was 1.46-fold higher in females compared to males. Case geographical mapping showed that Monterrey city recorded the majority of SARS-CoV-2 cases. These results show that there is a growing trend of seroprevalence over time associated with asymptomatic infection that is unnoticed under the current epidemiological surveillance protocols.

19 August 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
NCNestor Casillas-Vega
Nestor Casillas-Vega
FRFernanda Flores Rodríguez
Fernanda Flores Rodríguez
ISIsrael Sotelo-Coronado
Israel Sotelo-Coronado
MVMagda Elizabeth Vera-García
Magda Elizabeth Vera-García
AGAldo García-Heredia
Aldo García-Heredia
NHNorma Heredia
Norma Heredia
Little information is available regarding the pathogens that cause diarrhea in hospitalized patients who also have various clinical problems. The purpose of this study was to determine the presence of pathogens in fecal samples of hospitalized patients all suffering diarrhea in addition to other problems in Mexico. Diarrheic stools from 240 patients were obtained in a third-level hospital in Monterrey, Mexico. PCR was used for the detection of Salmonella spp., Shigella spp., Campylobacter spp., Yersinia spp., Aeromonas spp., Clostridioides difficile, and norovirus GI and GII. The presence of trophozoites, cysts of protozoa, eggs, and/or helminth larvae was determined by microscopic observation. Of the 240 patients analyzed, 40.4% presented at least one of the pathogens analyzed. Norovirus was the pathogen most frequently found (28.6%), followed by bacteria (11.7%), and parasites (8.3%). The majority of co-infections were parasites + norovirus, and bacteria + norovirus. Norovirus was detected mainly in children aged 0 to 10 years (9/15, 60%). Patients aged 0–20 years did not present co-infections. Entamoeba coli and Entamoeba histolytica were the most common parasites, (8/240), and Salmonella was the most prevalent bacteria (10/240). This information can help design specific strategies useful for hospitalized people with a compromised status.

30 November 2020 in medRxiv
Verified
Preprint
Open access
PDF file
NMNatalia Martinez-Acuña
Natalia Martinez-Acuña
Diana Nolazco-AvalosDiana Nolazco-Avalos
Diana Nolazco-Avalos
DRDiana Raquel Rodríguez-Rodríguez
Diana Raquel Rodríguez-Rodríguez
CMCynthia Martinez-Liu
Cynthia Martinez-Liu
RTRogelio Cazares Taméz
Rogelio Cazares Taméz
ARAna M. Rivas-Estilla
Ana M. Rivas-Estilla
Summary: Background: The progression and distribution of SARS-CoV-2 is unknown because typically only symptomatic individuals are diagnosed. Aim: We evaluated the seroprevalence of anti-SARS-CoV-2 in blood donors in Nuevo Leon, Mexico as a strategy for asymptomatic case detection of COVID-19 and epidemic progression. Methods/Materials: We tested 1968 blood donors that attended two regional donation centers in Northeast Mexico from January 1 st to August 30, 2020, to identify anti-SARS-CoV-2 IgG by chemiluminescent immunoassay. Additionally, routine tests for donors including Brucella, Chagas, HCV, VDRL, HIV-1, and HBsAg identification were performed. Results: We found 77 donors reactive for anti-SARS-CoV-2 IgG (seroprevalence 3.99%) and none of them had reported recent COVID-19 symptoms. Donors aged 18 to 49 years (89.5%) were more likely to be seropositive compared to those aged 50 years or older (10.5%) (P<0.001). Prevalence of antibodies increased each epidemiological (EPI) week, parallel to the report of confirmed cases by RT-PCR, identifying the highest prevalence between EPI week 33 and 35 (10.2% to 19%). The metropolitan area of Monterrey recorded the highest number of cases. Routine tests showed that the prevalence of anti-Brucella was 0.13%, anti-HCV 0.5%, anti-HIV-1-2 0.14%, HBsAg 0.16%, Chagas 0.48% and syphilis 1.06%. Conclusions: There is a growing trend of seroprevalence over time, parallel to the constantly increasing epidemic curve in our region and it was higher under 49 years of age associated with asymptomatic infection in donors from the Nuevo Leon area. Detection of anti-SARS-CoV-2 in blood donors is a potential tool for tracking the progression and identifying population exposure during the SARS-CoV-2 outbreak.